Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS

Aortic Valve Stenosis Clinical Trial

— EVoLVeD  

Official title:

Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients With Severe Aortic Stenosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03094143
• Other study ID #: 15/JTA
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 21, 2017
• Est. completion date: June 30, 2032

Study information

• Verified date: May 2024
• Source: University of Edinburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aortic stenosis is the most common valvular disease in the Western world. It is caused by progressive narrowing of the aortic valve leading to increased strain on the heart muscle which has to work increasingly hard to pump blood through the narrowed valve. Over time the heart muscle thickens to generate more force, but eventually the heart fails leading to death if the valve is not replaced with an operation. No medical treatments exist to stop or reverse the heart valve narrowing. Current clinical guidelines suggest that an operation should be performed only when symptoms develop or the heart muscle is visibly weak on cardiac ultrasound scanning. However, symptoms can be difficult to interpret and in many patients the heart muscle has become irreversibly damaged and the heart fails to recover following surgery.

Using MRI scans of the heart, the investigators have identified heart scarring which seems to develop as the heart muscle thickens. Several studies now show that people who have developed this scarring are more likely to suffer poor outcomes including death. The investigators have also identified clinical risks that predict the presence of scarring.

The investigators propose a study where patients with severe aortic stenosis but no indications for valve replacement as per current guidelines are assessed for those clinical risks. If a participant's risk of having scarring is higher they will undergo a cardiac MRI scan. If scarring is present participants will be randomised to routine clinical care, or referral for valve replacement surgery. Participants with no evidence of scarring will be randomised routine care with study follow or not. The investigators of this study hypothesize that early surgery will lead to fewer complications and reduced risk of death compared to standard care.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1000
• Est. completion date: June 30, 2032
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Severe aortic stenosis (aortic valve jet velocity =4.0 m/s, or aortic valve area indexed to body surface area <0.6cm2/m2 with aortic jet velocity =3.5m/s)

2. Age over 18 years

3. No symptoms attributable to aortic stenosis that require aortic valve replacement

Exclusion Criteria:

1. Deemed lower risk for mid-wall fibrosis on screening

2. Planned cardiac surgery

3. Previous valve replacement

4. Severe hypertension (systolic >180 or diastolic >110 mmHg)

5. Acute pulmonary oedema or cardiogenic shock

6. Left ventricular ejection fraction <50% on cardiac MRI

7. Significant abnormalities on cardiac MRI that would prevent enrolment

8. Coexistent severe aortic regurgitation or mitral regurgitation

9. Coexistent mitral stenosis greater than mild in severity

10. Coexistent hypertrophic cardiomyopathy or cardiac amyloidosis

11. Any contraindication to MRI scanning (such as permanent pacemaker)

12. Advanced renal impairment (glomerular filtration rate <30 mL/min/1.73 m2)

13. Pregnancy or breast feeding

14. Patient judged to be unfit to be considered for aortic valve replacement or transcatheter aortic valve implantation

15. Patient declines to consider undergoing valve replacement surgery or transcatheter aortic valve implantation

16. Inability to give informed consent

17. Previous randomisation into this study

Related Conditions & MeSH terms

• Aortic Valve Stenosis
• Constriction, Pathologic
• Hypertrophy
• Hypertrophy, Left Ventricular

Intervention

Procedure:
• Aortic valve intervention
The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.

Locations

Country	Name	City	State
United Kingdom	NHS Lothian	Edinburgh

Sponsors (2)

Lead Sponsor	Collaborator
University of Edinburgh	Sir Jules Thorn Charitable Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of all-cause mortality or unplanned aortic stenosis-related hospitalisation	The first event of all-cause mortality or unplanned aortic stenosis-related hospitalisation; Unplanned aortic stenosis-related hospitalisation is defined as an unplanned admission with syncope, heart failure, chest pain or arrhythmia (ventricular arrhythmia or second or third degree heart block) attributed to aortic stenosis. This endpoint will be adjudicated by two independent investigators blinded to the details of randomisation following review of the case notes and hospital records.	Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	All-cause mortality		Randomisation through to study completion, an average of 2.75 years
Secondary	Cardiovascular death		Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	AS-related death	AS-related death is a death where aortic stenosis has been listed as a contributory cause by the clinical care team on the patient's official death certificate.	Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	Sudden cardiac death		Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	Unplanned aortic-stenosis related hospitalisation	Unplanned aortic stenosis-related hospitalisation is defined as an unplanned admission with syncope, heart failure, chest pain or arrhythmia (ventricular arrhythmia or second or third degree heart block) attributed to aortic stenosis.	Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	WHODAS 2.0 (12 item)	The World Health Organization Disability Assessment Schedule (WHODAS 2.0) is a generic assessment instrument developed by WHO to provide a standardized method for measuring health and disability across cultures.	At study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	LV systolic function	The development of LV systolic dysfunction (EF <50% quantitatively or at least mild LV dysfunction qualitatively)	Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	NYHA status	Self reported patient symptoms on a scale of I-IV (I = No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, IV = Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.)	At study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	Permanent pacemaker insertion, cardiac resynchronisation therapy or automated implantable cardioverter defibrillator	To compare between study arms the number of participants who have had a permanent pacemaker insertion, cardiac resynchronisation therapy or automated implantable cardioverter defibrillator	Randomisation to through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	Stroke		Randomisation through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	Endocarditis	To compare between study arms the number of participants who have endocarditis	Randomisation to through to study completion (mean follow up is expected to be an average of 2.75 years)
Secondary	Post-operative complications following aortic valve intervention		30 days post aortic valve intervention